Skip to main content
Cancer Science logoLink to Cancer Science
. 2008 Apr 21;99(6):1202–1208. doi: 10.1111/j.1349-7006.2008.00812.x

Soy consumption reduces the risk of non‐small‐cell lung cancers with epidermal growth factor receptor mutations among Japanese

Keitaro Matsuo 1,6,, Akio Hiraki 1, Hidemi Ito 1, Takayuki Kosaka 2, Takeshi Suzuki 1, Kaoru Hirose 4, Kenji Wakai 5, Yasushi Yatabe 3, Tetsuya Mitsudomi 2, Kazuo Tajima 1,6
PMCID: PMC11159498  PMID: 18429954

Abstract

Epidermal growth factor receptor (EGFR) mutations play substantial roles in genesis and proliferation of non‐small‐cell lung cancers (NSCLCs). We recently found that reproductive factors have a substantial impact on risk of development of NSCLCs featuring such EGFR mutations. Therefore, we explored the influence of dietary habits on NSCLC risk with reference to the EGFR mutational status. We conducted a case‐control study using 353 patients with NSCLCs (122 EGFR mutated and 231 EGFR wild‐type) and 1765 age‐sex matched non‐cancer control subjects. Dietary exposure was based on a semiquantitative food frequency questionnaire and impact of major food items, like meats, seafoods, vegetables and soybean products was assessed by multivariate logistic regression. Soybean products demonstrated a protective association with EGFR mutated, but not EGFR wild‐type NSCLCs, with multivariate‐adjusted odds ratios and 95% confidence intervals for the 2nd and 3rd tertile of soybean product consumption of 0.79 (0.50–1.27) and 0.56 (0.34–0.93) relative to those in the lowest tertile (trend P = 0.023). In conclusion, soy consumption may exert a protective association against the development of NSCLCs with EGFR mutations, providing possible insights into mechanisms of their genesis. (Cancer Sci 2008; 99: 1202–1208)


The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that activates several signaling pathways resulting in cell proliferation, escape from apoptosis, and increased likelihood of invasion or metastasis, all of which are associated with the cancer phenotype.( 1 ) Elevated levels of EGFR are frequently seen in a variety of epithelial tumors( 2 ) including non‐small‐cell lung cancers (NSCLCs)( 3 , 4 ) and activating mutations of EGFR such as deletion in Exon 19 or point mutation at codon 858 have been reported in a subset of NSCLCs which are usually highly sensitive to kinase inhibitors such as gefitinib and erlotinib.( 5 , 6 , 7 ) Moreover, striking correlations between the EGFR mutation status and characteristics like a non‐smoking background, adenocarcinoma‐type, female sex, and East Asian ethnicity have been repeatedly demonstrated( 5 , 6 , 7 , 8 , 9 ) albeit without clarification of the reasons as yet. Previously, we demonstrated a significance of female sex and reproductive factors for risk of EGFR mutated (EGFRmut ) NSCLCs and suggested possible involvement of estrogenic factors in their genesis.( 10 ) Considering several pathological studies also demonstrated expression of hormonal receptors in NSCLCs, our former results motivated us to examine the impact of soy consumption, a primary source of the isoflavone phytestrogens well known to be associated with the hormone‐related breast cancer.( 11 , 12 , 13 , 14 )

Here, to assess the significance of dietary soy consumption with reference to the EGFR status of NSCLCs, in parallel with other food items, we conducted a case‐control study in 353 patients with NSCLCs and 1765 matched controls in a Japanese population.

Materials and Methods

Study subjects.  Subjects for this study were part of those in the previous report.( 10 ) A total of 353 patients diagnosed as having primary NSCLCs at the Department of Thoracic Surgery, Aichi Cancer Center Hospital (ACCH) and treated between January 2001 and February 2005 and 1765 age‐ and sex‐matched (1:5 case‐control ratio) non‐cancer patients who visited ACCH during the same period were examined. The reason for exclusion of the other 82 cases was lack of diet information by semiquantitative food‐frequency‐questionnaire (SQFFQ). Correspondingly, 410 matched‐controls were excluded. All the cases underwent potentially curative pulmonary resection at the Department of Thoracic Surgery, ACCH. The distribution of histological subtypes for NSCLCs among the 353 patients was 280 adenocarcinomas (79.3%), 18 large cell carcinomas (5.1%), 46 squamous cell carcinomas (13.0%) and 9 (2.6%) miscellaneous‐type lesions. Control subjects were eligible if they had no past history or current diagnosis of cancer.

All subjects were enrolled in the Hospital‐based Epidemiological Research Program at ACCH (HERPACC) at the time of their first visit to our hospital. The study frame‐work of this program has been detailed elsewhere.( 15 , 16 ) Briefly, all first‐visit outpatients at ACCH aged 18–79 years are asked to complete a self‐administered questionnaire on lifestyle factors which was then checked by trained interviewers. The questionnaire includes items on demographic characteristics, medical history, smoking and drinking habits, regular physical exercise, as well as menstrual and reproductive history and dietary habits before the development of current symptoms. To date, approximately 95% of eligible subjects have completed the questionnaire. All data are loaded into a HERPACC database and periodically linked with the hospital cancer registry system to update the data for cancer incidence. Like most general hospitals in Japan, the ACCH accepts new outpatients who visit of their own volition, with or without a doctor's referral. Thus, even though the ACCH is called a cancer hospital, only 19% of all new outpatients have cancer.( 17 ) Among non‐cancer outpatients, 45% present with no abnormal findings on clinical examination and 35% with benign non‐specific diseases.( 18 ) We previously showed that the lifestyle patterns of first‐visit outpatients accord with those of the general population randomly selected from residents of Nagoya City.( 19 ) Therefore, non‐cancer outpatients at ACCH can thus be regarded as appropriate controls for epidemiological studies. The present study was approved by the Institutional Ethics Review Board of ACCH, and all participants provided written informed consent.

EGFR mutation analysis.  Assays for EGFR mutations were described elsewhere.( 10 ) The majority of tumor samples were analyzed by reverse transcriptase‐polymerase chain reaction (RT‐PCR) coupled with direct sequencing. When frozen tissue for RT‐PCR was not available, the cases were examined with a DNA‐based assay using formalin‐fixed, paraffin‐embedded tissue. Both methods have been described in detail elsewhere.( 8 , 20 , 21 ) Briefly, total RNA was isolated using an RNAeasy kit (Qiagen, Valencia, CA, USA), followed by RT‐PCR with a QIAGEN OneStep RT‐PCR kit (Qiagen). The purified PCR products were directly sequenced with an ABI PRISM 3100 instrument (Applied Biosystems, Foster City, CA, USA). For DNA extracted from paraffin‐embedded tissues, we used the cycleave technique with the Smart Cycler system (SC‐100, Cepheid, Sunnyvale, CA, USA) and fragment analysis with the ABI PRISM 3100 for detection of point mutations of codon 858 and gene deletions in exon 19, which together account for approximately 90% of mutations in the EGFR gene.( 7 ) Comparability of two methods was 99% for condon 858 point mutation and deletion in exon 19 and was 95% for overall.( 21 )

Measurement of lifestyle exposure.  All exposures were assessed from the self‐administered questionnaire with checks by trained interviewers, as completed at the first visit to ACCH before the diagnostic procedure was conducted. Subjects were specifically questioned about their lifestyle before the onset of the symptoms which occasioned their visit to ACCH.

Smoking status was divided into three categories: never, former and current. Former smokers were defined as those who quit smoking at least 1 year before the time of the survey. Cumulative doses of smoking were evaluated as pack‐years (PYs), the product of the numbers of packs consumed in one day and the number of years of smoking. Age at starting smoking and years since quitting were asked of current smokers and former smokers, respectively. Alcohol consumption of each type of beverage (Japanese sake, beer, shochu, whiskey and wine) was determined by the average number of drinks per day, which was then converted into a Japanese sake (rice wine) equivalent, the ‘go’ (180 mL) which contains 23 g of ethanol. Total alcohol consumption was estimated as the sum of pure alcohol consumption in grams.

Consumption of food items was based upon the SQFFQ, for which validity and reproducibility have been described elsewhere.( 22 , 23 , 24 ) Our questionnaire covers 47 single food items with frequencies in the eight categories of never or seldom, 1–3 times/month, 1–2 times/week, 3–4 times/week, 5–6 times/week, once/day, twice/day, and three or more times/day. Values for the consumption of selected food groups (soybean, meat, fish, seafood other than fish, green‐yellow vegetables, vegetables other than green‐yellow vegetables, and fruits) were calculated as the sums of consumption of contributing single food items as estimated from the food frequency and portion size.

Statistical analysis.  We used STATA version 8 (STATA Corp., College Station, TX, USA) for all analyzes. The impact of each lifestyle factor was evaluated with odds ratios (ORs) in unconditional logistic regression models adjusted for age, sex and smoking. Conditional logistic regression models were not applied to avoid sparsity of data in stratified analysis. Differences in continuous variables between groups were evaluated by the Mann–Whitney test when appropriate. Food items were categorized into tertiles (T1 to T3) according to the distribution among controls. Trend tests were accomplished with scores which were defined as median value of each category in unconditional logistic regression models adjusted for age, sex, energy intake and smoking. We defined two‐sided P‐values of less than 0.05 as statistically significant.

Results

Baseline characteristics for the controls and cases are shown in Table 1. EGFRmut cases constituted approximately 35% among cases. As surgical cases tended to be checked for EGFR status, adenocarcinoma with histology was dominant. Smoking status significantly differed between the controls and the EGFRwt cases. Current smokers and heavy smokers (PY more than 40) were more common than in controls in EGFRwt but not EGFRmut cases. Alcohol drinking did not show any association, independent of the EGFR mutation status. Adenocarcinomas predominated among EGFRmut cases and even in the EGFRwt cases accounted for approximately two‐thirds.

Table 1.

Characteristics of controls and NSCLC cases seperated by EGFR mutation status

Male Female
Control Case Control Case
EGFRmut Comparison with controls (P‐values) EGFRwt Comparison with controls (P‐values) Comparison by mutation status (P‐values) EGFRmut Comparison with controls (P‐values) EGFRwt Comparison with controls (P‐values) Comparison by mutation status (P‐values)*
n 1080 46 170 685 76 61
Age (SD) 62.6 ± 9.4 62.8 ± 9.7 62.5 ± 9.4 60.7 ± 11.0 63.5 ± 8.8 57.2 ± 12.6
Smoking
 Never smoker 254 (23.5%) 14 (30.4%) 0.702 7 (4.1%) <0.001 <0.001 594 (86.7%) 69 (90.8%) 0.24 43 (70.5%) 0.003 0.004
 Former smoker 415 (38.4%) 15 (32.6%) 57 (33.5%) 26 (3.8%) 4 (5.3%) 5 (8.2%)
 Current smoker 408 (37.8%) 17 (37.0%) 106 (62.4%) 65 (9.5%) 3 (4.0%) 13 (21.3%)
 Unknown 3 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 0 pack‐years 255 (23.6%) 14 (30.4%) 0.563 7 (4.1%) <0.001 <0.001 594 (86.7%) 69 (90.8%) 0.018 43 (70.5%) <0.001 0.009
 1–40 pack‐years 448 (41.5%) 18 (39.1%) 43 (25.3%) 86 (12.6%) 4 (5.3%) 13 (21.3%)
 >40 pack‐years 352 (32.6%) 14 (30.4%) 115 (67.7%) 3 (0.4%) 2 (2.6%) 5 (8.2%)
 Unknown 25 (2.3%) 0 (0.0%) 5 (2.9%) 2 (0.3%) 1 (1.3%) 0 (0.0%)
Drinking
 Never drinker 300 (27.8%) 12 (26.1%) 0.611 48 (28.2%) 0.091 0.939 473 (69.1%) 50 (65.8%) 0.239 44 (72.1%) 0.837 0.342
 Former drinker 135 (12.5%) 3 (6.5%) 12 (7.1%) 24 (3.5%) 0 (0.0%) 1 (1.6%)
 Current drinker 644 (59.6%) 31 (67.4%) 109 (64.1%) 186 (27.2%) 26 (34.2%) 16 (26.2%)
 Unknown 1 (0.1%) 0 (0.0%) 1 (0.6%) 2 (0.3%) 0 (0.0%) 0 (0.0%)
Histopathology
 Adenocarcinoma 43 (93.5%) 110 (64.7%) 0.002 75 (98.7%) 52 (85.3%) 0.014
 Squamous cell carcinoma 2 (4.4%) 40 (23.5%) 0 (0.0%) 4 (6.6%)
 Large cell carcinoma 1 (2.2%) 13 (7.7%) 0 (0.0%) 4 (6.6%)
 Others 0 (0.0%) 7 (4.1%) 1 (1.3%) 1 (1.6%)
*

P‐values were calculated for homogeneity across three groups.

Mann–Whitney ranksum test was applied.

EGFR, epidermal growth factor receptor; SD, standard deviation.

Table 2 shows the impact of food groups on EGFRmut and EGFRwt NSCLCs. Consumption of soybean products was associated with a statistically significant decrease in the risk of EGFRmut NSCLCs. ORs for the second and third tertiles in comparison with the lowest tertile were thus 0.79 (0.50–1.27) and 0.56 (0.34–0.93), the trend being statistically significant (P = 0.023). Consumption of other food products including meat, fish and seafood showed no significant influence on either type of NSCLC. Intake of vegetables exhibited a significant protective association only for EGFRwt NSCLCs and similarly protective trend was observed with fruits and vegetables other than green‐yellow vegetables.

Table 2.

Impact of selected food group intake on NSCLC with or without EGFR mutation

Item (median, range) Total
Control Case
EGFRmut EGFRwt
N OR (95% CI) N OR (95% CI)
Soybean products
T1 (19.8, 0.0–32 g/day) 586 46 1.00 (Reference) 84 1.00 (Reference)
T2 (44.1, 33–54.6 g/day) 586 43 0.79 (0.50–1.27) 87 1.19 (0.85–1.68)
T3 (81.8, 54.7–300 g/day) 585 33 0.56 (0.34–0.93)
P for trend = 0.023 60 0.89 (0.61–1.29)
P for trend = 0.499
Meat
T1 (12.5 0.0–21.3 g/day) 586 41 1.00 (Reference) 82 1.00 (Reference)
T2 (26.6, 21.4–32.6 g/day) 586 37 0.90 (0.55–1.48) 84 1.11 (0.79–1.57)
T3 (54.1, 32.7–230 g/day) 585 44 1.15 (0.71–1.86)
P for trend = 0.576 65 0.79 (0.55–1.14)
P for trend = 0.259
Fish
T1 (14.4 0.0–20.1 g/day) 586 39 1.00 (Reference) 85 1.00 (Reference)
T2 (35.4, 20.2–43.1 g/day) 586 43 1.00 (0.62–1.63) 83 1.07 (0.76–1.50)
T3 (64.9, 43.2–270 g/day) 585 40 0.98 (0.59–1.62)
P for trend = 0.939 63 0.80 (0.55–1.16)
P for trend = 0.273
Other seafood
T1 (8.39, 0.0–12.0 g/day) 586 41 1.00 (Reference) 80 1.00 (Reference)
T2 (15.7, 12.0–18.7 g/day) 586 35 0.87 (0.53–1.42) 77 1.01 (0.71–1.44)
T3 (31.7, 18.8–150 g/day) 585 46 1.19 (0.74–1.91)
P for trend = 0.480 74 0.92 (0.65–1.32)
P for trend = 0.668
Green‐yellow vegetables
T1 (25.3, 0.0–39.8 g/day) 586 37 1.00 (Reference) 103 1.00 (Reference)
T2 (57.8, 39.9–76.8 g/day) 586 45 1.06 (0.64–1.74) 75 0.78 (0.56–1.10)
T3 (123.4, 76.9–500 g/day) 585 40 0.76 (0.45–1.29)
P for trend = 0.282 53 0.69 (0.47–1.00)
P for trend = 0.044
Other vegetables
T1 (24.7, 0.0–41.6 g/day) 586 42 1.00 (Reference) 99 1.00 (Reference)
T2 (55.5, 41.7–70.2 g/day) 586 36 0.81 (0.49–1.33) 69 0.72 (0.51–1.02)
T3 (107.5, 70.3–410 g/day) 585 44 0.84 (0.51–1.37)
P for trend = 0.525 63 0.78 (0.53–1.11)
P for trend = 0.158
Fruit
T1 (21.9, 0.0–33.9 g/day) 586 35 1.00 (Reference) 98 1.00 (Reference)
T2 (70.5, 34.0–84.9 g/day) 586 37 0.93 (0.55–1.56) 78 0.91 (0.65–1.27)
T3 (151.2, 85.0–510 g/day) 585 50 1.10 (0.66–1.85)
P for trend = 0.602 55 0.72 (0.49–1.06)
P for trend = 0.096

Eight controls were excluded from analysis due to incomplete SQFFQ data.

ORs were adjusted for age, sex, energy intake, and smoking in unconditional logistic model.

EGFR, epidermal growth factor receptor; CI, confidence interval; NSCLC, non‐small‐cell lung cancers; OR, odds ratio.

The results of stratified analyzes by sex, age, smoking and histology are shown in Table 3. Soybean product intake conferred a significantly decreased risk for EGFRmut but not EGFRwt NSCLCs in males. A similar trend was observed in females treated separately, although without significance. Regarding age, protective association of soy consumption for EGFRmut NSCLCs were clearly seen in the younger age groups (<55 and 55–64 years), while being less clear at older ages. At all levels of smoking, soy consumption showed risk reduction for EGFRmut NSCLCs, though not significant. With EGFRwt NSCLCs, the middle level exposure group (1–40 PYs) showed a decreased risk; increased risk was observed for never smokers; and no change was observed for the high level exposure group. Taking into account the histopathology, protective association were clear for EGFRmut but not EGFRwt adenocarcinomas. Due to the small number of cases EGFRmut nonadenocarcinomas were difficult to evaluate. Stratified analysis for menopausal status among women showed a protective association for EGFRwt NSCLCs among premenopausal women, although very small number of cases might limit interpretability. EGFRwt NSCLCs did not show any significant protective association of soy consumption.

Table 3.

Impact of soybean product intake on NSCLC with or without EGFR mutation

Control Cases
EGFRmut EGFRwt
Soy consumption (n) Soy consumption [n, OR (95%CI)] Soy consumption [n, OR (95% CI)]
T1 T2 T3 T1 T2 T3 Trend‐P T1 T2 T3 Trend‐P
Sex
Male 379 344 353 20 17 9 64 67 39
1.00 (Reference) 0.94 (0.45–1.96) 0.39 (0.16–0.94) 0.035 1.00 (Reference) 1.21 (0.81–1.79) 0.74 (0.47–1.16) 0.243
Female 207 242 232 26 26 24 20 20 21
1.00 (Reference) 0.73 (0.39–1.35) 0.67 (0.35–1.25) 0.238 1.00 (Reference) 1.18 (0.59–2.37) 1.39 (0.68–2.83) 0.365
Age
<55 175 124 108 12 8 5 32 17 8
1.00 (Reference) 0.66 (0.24–1.85) 0.49 (015–1.59) 0.221 1.00 (Reference) 0.91 (0.47–1.76) 0.56 (0.24–1.34) 0.227
55–64 174 206 182 19 12 7 23 29 23
1.00 (Reference) 0.47 (0.21–1.05) 0.36 (0.14–0.95) 0.026 1.00 (Reference) 1.16 (0.62–2.15) 0.99 (0.51–1.92) 0.979
65–79 237 256 295 15 23 21 29 41 29
1.00 (Reference) 1.38 (0.66–2.87) 0.85 (0.41–1.79) 0.547 1.00 (Reference) 1.60 (0.92–2.78) 1.06 (0.59–1.90) 0.861
Smoking §
0 pack‐years 256 281 306 30 27 26 13 16 21
1.00 (Reference) 0.69 (0.38–1.25) 0.59 (0.32–1.07) 0.094 1.00 (Reference) 1.40 (0.63–3.14) 2.11 (0.96–4.63) 0.058
1–40 pack‐years 191 181 161 8 10 4 27 19 10
1.00 (Reference) 1.49 (0.50–4.39) 0.55 (0.15–2.04) 0.358 1.00 (Reference) 0.80 (0.42–1.52) 0.47 (0.21–1.03) 0.059
>40 pack‐years 131 116 108 8 5 3 43 49 28
1.00 (Reference) 0.70 (0.19–2.63) 0.42 (0.09–2.07) 0.282 1.00 (Reference) 1.33 (0.80–2.21) 0.83 (0.47–1.48) 0.515
Histopathology
Adenocarcinoma 470 464 460 44 41 33 54 64 44
1.00 (Reference) 0.79 (0.49–1.28) 0.59 (0.35–0.98) 0.042 1.00 (Reference) 1.36 (0.92–2.03) 1.01 (0.65–1.57) 0.957
non‐Adenocarcinoma 116 122 125 2 2 0 30 23 16
1.00 (Reference) 0.90 (0.12–6.55) NE †† 0.187 1.00 (Reference) 0.78 (0.41–1.48) 0.58 (0.29–1.16) 0.124
Menopausal status ‡‡
Premenopausal 50 40 29 6 2 1 7 5 2
1.00 (Reference) 0.20 (0.03–1.26) 0.11 (0.01–1.12) 0.037 1.00 (Reference) 1.15 (0.32–4.10) 0.77 (0.13–4.38) 0.858
Postmenopausal 156 201 202 20 17 9 64 68 39
1.00 (Reference) 0.90 (0.46–1.75) 0.84 (0.43–1.66) 0.623 1.00 (Reference) 1.18 (0.50–2.81) 1.60 (0.70–3.67) 0.253

Eight controls were excluded from analyzes due to incomplete SQFFQ status.

ORs were adjusted for age, sex, energy intake and smoking in unconditional logistic model.

§

Twenty‐seven controls and six cases were excluded because of unknown status.

Controls matched with adenocarcinoma cases were used for adenocarcinoma analysis. Same condition is applied to nonadenocarcinoma analysis.

†† NE indicate not estimate due to lack of case in this category.

‡‡

Analysis was limited to female with known menopausal status.EGFR, epidermal growth factor receptor; CI, confidence interval; NSCLC, non‐small‐cell lung cancers; OR, odds ratio; SQFFQ, semiquantitative food‐frequency‐questionnaire.

We further examined the single food items contributing to total soy consumption, miso soup, natto (fermented soy) and tofu as shown in Table 4. Miso soup consumption conferred a statistically significantly decreased risk of EGFRmut NSCLC overall and in males. A non‐significant similar trend was observed for females. High consumption of natto also showed protective association for EGFRmut but not for EGFRwt tumors. Associations between risk and tofu consumption were not obvious overall as well as in each sex.

Table 4.

Impact of soy and soy‐containing food items on NSCLC with or without EGFR mutation

Item Total Male Female
Control Case Control Case Control Case
EGFRmut OR (95% CI) EGFRwt OR (95% CI) EGFRmut OR (95% CI) EGFRwt OR (95% CI) EGFRmut OR (95% CI) EGFRwt OR (95% CI)
Miso soup
≤3–4 times/week 758 62 1.00 (Reference) 99 1.00 (Reference) 433 25 1.00 (Reference) 69 1.00 (Reference) 325 37 1.00 (Reference) 30 1.00 (Reference)
≤once a day 811 56 0.69 (0.46–1.03) 103 1.08 (0.79–1.48) 512 20 0.46 (0.24–0.91) 81 1.12 (0.78–1.61) 299 36 0.87 (0.52–1.45) 22 1.00 (0.54–1.82)
twice a day 152 3 0.23 (0.07–0.77) 22 1.17 (0.70–1.96) 110 1 0.12 (0.02–0.92) 15 0.90 (0.49–1.68) 42 2 0.35 (0.08–1.57) 7 2.33 (0.89–6.15)
Unknown 44 1 7 25 0 5 19 1 2
P for trend = 0.005 P for trend = 0.499 P for trend = 0.003 P for trend = 0.946 P for trend = 0.216 P for trend = 0.252
Natto
≤1–3 times/month 550 42 1.00 (Reference) 91 1.00 (Reference) 387 21 1.00 (Reference) 70 1.00 (Reference) 163 21 1.00 (Reference) 21 1.00 (Reference)
≥3–4 times/week 864 57 0.63 (0.40–0.99) 98 0.85 (0.61–1.16) 490 17 0.57 (0.28–1.17) 72 0.89 (0.61–1.29) 374 40 0.69 (0.38–1.22) 26 0.71 (0.38–1.35)
≥once a day 301 21 0.59 (0.33–1.06) 32 0.91 (0.58–1.43) 174 8 0.56 (0.22–1.43) 20 0.84 (0.48–1.47) 127 13 0.62 (0.29–1.34) 12 1.01 (0.45–2.29)
Unknown 50 2 10 29 0 8 21 2 2
P for trend = 0.052 P for trend = 0.482 P for trend = 0.150 P for trend = 0.467 P for trend = 0.199 P for trend = 0.839
Tofu
≤1–3 times/month 570 35 1.00 (Reference) 73 1.00 (Reference) 387 22 1.00 (Reference) 56 1.00 (Reference) 179 13 1.00 (Reference) 17 1.00 (Reference)
1–2 times/week 617 50 1.07 (0.66–1.74) 88 1.30 (0.92–1.84) 490 13 0.54 (0.25–1.15) 70 1.33 (0.90–1.97) 238 37 1.85 (0.93–3.69) 18 1.06 (0.51–2.23)
≥3–4 times/week 509 34 0.80 (0.48–1.36) 62 1.14 (0.78–1.66) 174 10 0.61 (0.27–1.39) 37 0.97 (0.61–1.53) 239 24 1.15 (0.55–2.38) 25 1.46 (0.73–2.94)
Unknown 69 3 8 29 1 7 29 2 1
P for trend = 0.398 P for trend = 0.450 P for trend = 0.170 P for trend = 0.946 P for trend = 0.988 P for trend = 0.269

ORs were adjusted for age, sex and smoking in unconditional logistic model. Unknown subjects were excluded from trend analysis.

EGFR, epidermal growth factor receptor; CI, confidence interval; NSCLC, non‐small‐cell lung cancers; OR, odds ratio.

Discussion

In this study of the impact of food consumption on the risk NSCLCs divided by EGFR mutation status, soy consumption was found to be significantly associated with a lowered risk of EGFRmut but not EGFRwt NSCLCs. To our knowledge, this is the first indication that soy consumption may influence molecular events contributing to the subset of NSCLCs featuring EGFR mutations, as the hormonal receptor status of breast cancers is known to be affected by reproductive factors.( 25 )

Soy products contain isoflavones, phytestrogens such as genistein, daizein and glycitein( 12 ) and there is strong epidemiologic evidence of protective effects of soy consumption for breast cancer.( 11 , 12 , 13 , 14 ) In the present study, a relatively higher consumption of soybean products decreased the risk of NSCLCs with EGFR mutations only. In addition, we and others have previously reported that soy product consumption is associated with a decreased risk of all NSCLCs.( 26 , 27 , 28 , 29 ) These findings may provide insights into both the genesis and differentiation of NSCLCs. Soybean isoflavones are heterocyclic phenols closely related in structure to estrogen and their very weak estrogenic activity despite higher affinity for estrogen receptors than estrogens themselves endows them with antiestrogenic effects.( 30 ) Several epidemiologic studies have shown associations between reproductive factors and NSCLC risk, although the direction of the impact was not consistent.( 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ) Moreover, we previously reported elevated risk with a longer fertile life supporting a positive association between estrogenic exposure in NSCLCs and EGFR mutation.( 10 ) Taken the data together, one may hypothesize that hormones play an important role in EGFR mutagenesis in the lung or outcome in lesions bearing EGFR mutations.

The weaker association in females is one of the limitation of this interpretation, suggesting other possibility for soy's impact on EGFR mutation status. Soy products may exert various nonestrogenic effects, reviewed in detail by Messina et al.( 30 ) The inhibitory effect of genistein on tyrosine kinase( 41 , 42 ) might be relevant to the question of the putative involvement of soy products in the EGFR‐mediated phosphorylation cascade in EGFRmut NSCLCs. Further, Peterson et al. reported that genistein inhibits EGFR‐mediated signal transduction distal to EGFR tyrosine autophosphorylation.( 43 ) The epidemiologic association as well as biological significance of soy products thus requires further evaluation.

In our study, consumption of fruits and vegetables showed protective association only for EGFRwt NSCLC. Fruit and vegetable consumption is regarded as convincing protective factors for smoking related cancers occurring, including lung, and possible mechanisms behind this association include antioxidative effect by micronutrients such as beta‐carotene, vitamins C and E.( 44 ) Our current finding are accordant with our previous finding that EGFRwt NSCLC were smoking related NSCLC.( 10 )

Several methodological points with this study should be addressed. First, most remarkable advantage of this study is an availability of EGFR mutational status for hundreds of cases along with lifestyle data. This situation is rarely available with population‐based study setting. Next, all lifestyle information was based on self‐reporting, there could be the possibility of information bias; however, regarding bias in soy consumption, it is unlikely having disease change subjects’ response because effect of soy on NSCLC have never been accepted in public. Moreover, as the data were collected before diagnosis and patients with NSCLCs had no information regarding their EGFR mutation status, bias due to having the disease seems again unlikely. The hospital‐based design could be another limitation; however, similarity in lifestyle between our controls and population( 19 ) might warrant appropriateness of our study. Finally, our study was limited to ethnic Japanese and the results therefore cannot necessarily be extrapolated to other population groups. Considering the higher consumption of soy products in Japan than in Western countries, and their potential protective effects against EGFR‐mutated NSCLCs, evaluations in other population is important. Also, there might be unknown genetic difference in regard to risk of EGFR mutation, further evaluation requires taking genetic background in the population into consideration.

In conclusion, the present findings provide evidence that soy product consumption reduces the risk of EGFR‐mutated NSCLCs. Further investigation of these findings in other ethnic groups is warranted.

Acknowledgments

This study was supported by a Grant‐in Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture and Technology of Japan, a Grant‐in‐Aid for Cancer Research from the Ministry of Health, Labour and Welfare, and by a Grant‐in‐Aid for the Third Term Comprehensive 10‐Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan.

Authors are grateful for the technical support by the staff of Division of Epidemiology and Prevention, Nagoya, Japan.

References

  • 1. Hunter T, Cooper JA. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell 1981; 24: 741–52. [DOI] [PubMed] [Google Scholar]
  • 2. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl. 4): S9–15. [DOI] [PubMed] [Google Scholar]
  • 3. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29 (Suppl. 14): 3–9. [DOI] [PubMed] [Google Scholar]
  • 4. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non‐small cell lung cancer. Semin Oncol 2002; 29 (Suppl. 14): 38–44. [DOI] [PubMed] [Google Scholar]
  • 5. Paez JG, Janne PA, Lee JC et al . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500. [DOI] [PubMed] [Google Scholar]
  • 6. Lynch TJ, Bell DW, Sordella R et al . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non‐small‐cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39. [DOI] [PubMed] [Google Scholar]
  • 7. Pao W, Miller V, Zakowski M et al . EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919–23. [DOI] [PubMed] [Google Scholar]
  • 9. Shigematsu H, Lin L, Takahashi T et al . Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–46. [DOI] [PubMed] [Google Scholar]
  • 10. Matsuo K, Ito H, Yatabe Y et al . Risk factors differ for non‐small‐cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case‐control study in Japanese. Cancer Sci 2007; 98: 96–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Adlercreutz H, Mazur W. Phyto‐oestrogens and Western diseases. Ann Med 1997; 29: 95–120. [DOI] [PubMed] [Google Scholar]
  • 12. Adlercreutz H. Phyto‐oestrogens and cancer. Lancet Oncol 2002; 3: 364–73. [DOI] [PubMed] [Google Scholar]
  • 13. Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A. Phyto‐oestrogens: where are we now? Br J Nutr 1998; 79: 393–406. [DOI] [PubMed] [Google Scholar]
  • 14. Sarkar FH, Li Y. The role of isoflavones in cancer chemoprevention. Front Biosci 2004; 9: 2714–24. [DOI] [PubMed] [Google Scholar]
  • 15. Tajima K, Hirose K, Inoue M, Takezaki T, Hamajima N, Kuroishi T. A Model of practical cancer prevention for out‐patients visiting a hospital: the hospital‐based epidemiologic research program at aichi cancer center (HERPACC). Asian Pac J Cancer Prev 2000; 1: 35–47. [PubMed] [Google Scholar]
  • 16. Hamajima N, Matsuo K, Saito T et al . Gene–environment interactions and polymorphism studies of cancer risk in the hospital‐based Epidemiologic Research Program at Aichi Cancer Center II (HERPACC‐II). Asian Pac J Cancer Prev 2001; 2: 99–107. [PubMed] [Google Scholar]
  • 17. Inoue M, Tajima K, Takezaki T et al . Epidemiology of pancreatic cancer in Japan: a nested case‐control study from the Hospital‐based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Int J Epidemiol 2003; 32: 257–62. [DOI] [PubMed] [Google Scholar]
  • 18. Inoue M, Tajima K, Hirose K et al . Subsite‐specific risk factors for colorectal cancer: a hospital‐based case‐control study in Japan. Cancer Causes Control 1995; 6: 14–22. [DOI] [PubMed] [Google Scholar]
  • 19. Inoue M, Tajima K, Hirose K et al . Epidemiological features of first‐visit outpatients in Japan: comparison with general population and variation by sex, age, and season. J Clin Epidemiol 1997; 50: 69–77. [DOI] [PubMed] [Google Scholar]
  • 20. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005; 29: 633–9. [DOI] [PubMed] [Google Scholar]
  • 21. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006; 24: 1679–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Tokudome S, Goto C, Imaeda N, Tokudome Y, Ikeda M, Maki S. Development of a data‐based short food frequency questionnaire for assessing nutrient intake by middle‐aged Japanese. Asian Pac J Cancer Prev 2004; 5: 40–3. [PubMed] [Google Scholar]
  • 23. Tokudome S, Ikeda M, Tokudome Y, Imaeda N, Kitagawa I, Fujiwara N. Development of data‐based semi‐quantitative food frequency questionnaire for dietary studies in middle‐aged Japanese. Jpn J Clin Oncol 1998; 28: 679–87. [DOI] [PubMed] [Google Scholar]
  • 24. Tokudome Y, Goto C, Imaeda N et al . Relative validity of a short food frequency questionnaire for assessing nutrient intake versus three‐day weighed diet records in middle‐aged Japanese. J Epidemiol 2005; 15: 135–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Althuis MD, Fergenbaum JH, Garcia‐Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor‐defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13: 1558–68. [PubMed] [Google Scholar]
  • 26. Takezaki T, Hirose K, Inoue M et al . Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas. Br J Cancer 2001; 84: 1199–206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Koo LC. Dietary habits and lung cancer risk among Chinese females in Hong Kong who never smoked. Nutr Cancer 1988; 11: 155–72. [DOI] [PubMed] [Google Scholar]
  • 28. Swanson CA, Mao BL, Li JY et al . Dietary determinants of lung‐cancer risk: results from a case‐control study in Yunnan Province, China. Int J Cancer 1992; 50: 876–80. [DOI] [PubMed] [Google Scholar]
  • 29. Wakai K, Ohno Y, Genka K et al . Risk modification in lung cancer by a dietary intake of preserved foods and soyfoods: findings from a case‐control study in Okinawa, Japan. Lung Cancer 1999; 25: 147–59. [DOI] [PubMed] [Google Scholar]
  • 30. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113–31. [DOI] [PubMed] [Google Scholar]
  • 31. Gao YT, Blot WJ, Zheng W et al . Lung cancer among Chinese women. Int J Cancer 1987; 40: 604–9. [DOI] [PubMed] [Google Scholar]
  • 32. Wu AH, Yu MC Thomas DC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988; 48: 7279–84. [PubMed] [Google Scholar]
  • 33. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994; 86: 869–70. [DOI] [PubMed] [Google Scholar]
  • 34. Zhou BS, Wang TJ, Guan P, Wu JM. Indoor air pollution and pulmonary adenocarcinoma among females: a case‐control study in Shenyang, China. Oncol Rep 2000; 7: 1253–9. [DOI] [PubMed] [Google Scholar]
  • 35. Liao ML, Wang JH, Wang HM, Ou AQ, Wang XJ, You WQ. A study of the association between squamous cell carcinoma and adenocarcinoma in the lung, and history of menstruation in Shanghai women, China. Lung Cancer 1996; 14 (Suppl. 1): S215–21. [DOI] [PubMed] [Google Scholar]
  • 36. Seow A, Poh WT, Teh M et al . Diet, reproductive factors and lung cancer risk among Chinese women in Singapore: evidence for a protective effect of soy in nonsmokers. Int J Cancer 2002; 97: 365–71. [DOI] [PubMed] [Google Scholar]
  • 37. Kubik AK, Zatloukal P, Tomasek L, Petruzelka L. Lung cancer risk among Czech women: a case‐control study. Prev Med 2002; 34: 436–44. [DOI] [PubMed] [Google Scholar]
  • 38. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int J Epidemiol 2003; 32: 263–71. [DOI] [PubMed] [Google Scholar]
  • 39. Brenner AV, Wang Z, Kleinerman RA et al . Menstrual and reproductive factors and risk of lung cancer among Chinese women, Eastern Gansu Province, 1994–98. J Epidemiol 2003; 13: 22–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle‐aged never‐smoking Japanese women: a large‐scale population‐based cohort study. Int J Cancer 2005; 117: 662–6. [DOI] [PubMed] [Google Scholar]
  • 41. Cunningham BD, Threadgill MD, Groundwater PW, Dale IL, Hickman JA. Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases. Anticancer Drug Des 1992; 7: 365–84. [PubMed] [Google Scholar]
  • 42. Kuriu A, Ikeda H, Kanakura Y et al . Proliferation of human myeloid leukemia cell line associated with the tyrosine‐phosphorylation and activation of the proto‐oncogene c‐kit product. Blood 1991; 78: 283d–40. [PubMed] [Google Scholar]
  • 43. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993; 22: 335–45. [DOI] [PubMed] [Google Scholar]
  • 44. No author listed . Vegetables and fruits. In: Cannon G, ed. Food, Nutrition and the Prevention of Cancer: a Global Perspective: World Cancer Research Fund/American Institute for Cancer Research 1997. American Institute for Cancer Research: Washington, DC; 436–46.

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES